KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$7.50 USD
+0.73 (10.78%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.45 -0.05 (-0.67%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KALA 7.50 +0.73(10.78%)
Will KALA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KALA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALA
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
KALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for KALA
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News
Kala Pharmaceuticals initiated with bullish view at Ladenburg, here's why
KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KPI-012 | KALA Stock News
Kala completes patient enrollment for CHASE Phase 2 clinical trial